Eur Neuropsychopharmacol. 2010 Nov; 20 (11): 766-75. doi: 10.1016 / j.euroneuro.2010.07.010. Epub 2010 Sep 1.
Peterson E1, Møller A, ʻLelo Hana ʻo Doudet, ʻO Bailey CJ, Hansen KV, Rodell A., Linnet J, Gjedde A.
Hōʻuluʻulu Manaʻo
Hiki ke pili i ka pane ʻana o ka ʻili absent (SCR) i ka piliwaiwai pathological (PG) i nā ʻano dopaminergic. Ua hōʻiliʻili mākou i nā helu like o nā kumuhana PG a me nā kumumanaʻo olakino olakino (HC), a laila ua hoʻāʻo i ka ʻōlelo e hoʻemi ʻia ka SCR e ka hana dopaminergic i nā kumuhana PG. I ka wā o ka piliwaiwai ʻeleu, ʻokoʻa ʻo SCR i nā kumuhana PG a me HC (P <0.05), akā ua hōʻike ka posograpon emission tomography i ka loaʻa like o ka receptor like me ka dopamine. Eia nō naʻe, loaʻa i nā poʻe PG ʻimi ʻimi naʻau (HS) PG nā loaʻa o ka receptor haʻahaʻa (P <0.0001) i ka laina, ke hoʻohālikelike ʻia i nā kumuhana PG ʻimi ʻimi maʻamau (NS). ʻIke mākou ua like ka nānā ʻana o HS a me nā mana NS i ka hoʻonui nui ʻana o ka hiki paʻa (BP (ND)) i ke kiʻekiʻe ke hoʻohālikelike ʻia me nā ʻimi ʻimi maʻamau. I nā hui ʻelua, ʻo PG a me HC, nā mea ʻimi ʻimi loa i hoʻonui i ka loaʻa o ka receptor i striatum, hoʻohālikelike ʻia me nā ʻimi ʻimi ʻimi maʻamau, ʻokoʻa (P <0.05 a me P = 0.02) a me (P <0.0005). Hoʻoholo mākou ua ʻoi aku ka liʻiliʻi o SCR e ka hana dopaminergic i nā kumuhana e ʻimi nei i ka manaʻo nui, me ka nānā ʻole i ke kūlana PG.
;